A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Northwestern University
- Enrollment
- 43
- Primary Endpoint
- Sinus CT Scan Scores by Lund-Mackay Scores
Study Overview
Brief Summary
To evaluate the efficacy of an anti-inflammatory agent compared with placebo in relieving signs and symptoms of disease in patients with sinusitis.
Detailed Description
This is a Phase 2a, single-center, randomized, placebo-controlled, double-blind study that includes 12 weeks of treatment with experimental drug anti-inflammatory agent or placebo TID administered orally.
All subjects will be ≥18 years, have sinusitis with persistent symptoms despite standard of care treatment, and have failed a course of steroids in the past.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females must have a negative urine pregnancy test at screening unless documented to have a hysterectomy or be postmenopausal.
Exclusion Criteria
- •Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- •Use of any investigational drugs within 30 days of screening.
- •Acute infection needing antibiotic treatment at screening.
Arms & Interventions
AZ Compound
40 mg 12 weeks TID po
Intervention: AZ compound (Drug)
Placebo
40 mg 12 weeks TID po
Intervention: Intranasal corticosteroid (Drug)
AZ Compound
40 mg 12 weeks TID po
Intervention: Collection of Biological Specimens (Other)
AZ Compound
40 mg 12 weeks TID po
Intervention: Intranasal corticosteroid (Drug)
Placebo
40 mg 12 weeks TID po
Intervention: Placebo (Drug)
Placebo
40 mg 12 weeks TID po
Intervention: Collection of Biological Specimens (Other)
Outcomes
Primary Outcomes
Sinus CT Scan Scores by Lund-Mackay Scores
Time Frame: Baseline and Week 12
Measurement of secondary outcome: sinus CT scan scores by Lund-Mckay scores. We measured sinus radiographic severity with Lund-Mackay scores of 0 to 24. 0 was the least severe and 24 was the most severe. This secondary outcomes included change in radiographic severity of sinus disease, as measured by sinus CT scan scores at baseline and 12 weeks in the AZD1981 group vs. the placebo group.
BSIT (Brief Smell Identification Test)
Time Frame: Baseline and Week 12
Measurement of secondary outcome- BSIT (brief smell identification test) is a 12-item test measuring sense of smell. This is a multiple choice test with one correct answer out of four possible answer choices. This test features distinct types of smells. Minimum score: 0/12, which indicates that none of the correct answers were chosen on the 12-item test. Maximum score: 12/12, which indicates that all of the correct answers were chosen on the 12-item test. The higher the score, the better the outcome. Only one out of the four possible answer choices for each multiple choice question is correct. There are no subscales. This secondary outcome measures sense of smell by Brief Smell Identification Test (B-SIT) at baseline (visit 1) and 12 weeks (visit 5) in the AZD1981 group vs. the placebo group.
TOTAL POLYP SCORE (TPS)
Time Frame: Baseline and Week 12
Measure Description: Measurement of Primary outcome- 0-4 scale in each nostril, total is 8. The total polyp score is the sum of the right and left nasal polyp score. Maximum is 8, minimum is 0. Higher score indicates worse disease. 0 =No polyps 1=Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate 2=Polyps reaching the lower border of the middle turbinate or polyp medial to the middle turbinate 3 = Large polyps reaching the lower border of the inferior turbinate 4 =Large polyps causing complete obstruction. The primary outcome measured change in polyp size and secondary outcomes included change in radiographic severity of sinus disease, quality of life, and nasal symptoms as measured by Sino Nasal Outcome Test-22 (SNOT-22) and sense of smell by Brief Smell Identification Test (B-SIT) at 12 weeks in the AZD1981 group vs. the placebo. These were done at the baseline visit and the Week 12 visit.
Secondary Outcomes
- SNOT-22 (Sino-Nasal Outcome Test-22) Score(Baseline and Week 12)
- Visual Analog Scale (VAS)(Baseline and Week 12)
Investigators
Anju Peters
Principal Investigator
Northwestern University
